p53 mutations and expression in ovarian cancers: Correlation with overall survival

International Journal of Gynecological Pathology

Volumn 18, Issue 1, 1999, Pages 29-41

  Wen, Wen Hsiang ^a   Reles, Angela ^a,c   Runnebaum, Ingo B ^d   Sullivan Halley, Jane ^a,b   Bernstein, Leslie ^b   Jones, Lovell A ^e   Felix, Juan C ^a   Kreienberg, Rolf ^d   El Naggar, Adel ^e   Press, Michael F ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Immunohistochemistry; Ovarian cancer; p53 mutations; p53 tumor suppressor gene; Prognosis

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OPEN READING FRAME; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0032960167     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199901000-00005     Document Type: Article

References (61)

1. Parker S, Tong T, Bolden S, Wingo P. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Qazi F, McGuire W. The treatment of epithelial ovarian cancer. CA Cancer J Clin 1995;45:88-101.
3. Wingo P, Tong T, Bolden S, Cancer statistics. CA Cancer J Clin 1995;45:8-30.
4. Teneriello M, Park R, Early detection of ovarian cancer. CA Cancer J Clin 1995;45:71-87.
5. Greenblatt M, Harris C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
6. Kohler M, Kerns B, Berchuck A. Mutation and overexpression of p53 in early stage epithelial ovarian cancer. Obstet Gynecol 1993a;81:643-50.
7. Kohler M, Marks J, Wiseman R, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. JNCI 1993b;85(18):1513-9.
8. Kupryjanczyk J, Thor A, Beauchamp R, Merritt V, Edgerton S, Bell D, Yandell D. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90: 4961-5.
9. Fujita M, Enomoto T, Inoue M, Tanizawa O, Ozaki M, Rice J, Nomura T. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinoma than in other common epithelial tumors of the human ovary. Jpn J Cancer Res 1994;85:1247-56.
10. Vogelstein B. Clinical implication of basic research: Cancer therapy meets p53. N Engl J Med 1994;331(1):49-50.
11. Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, Yokota J. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991;51:5171-6.
12. Marks J, Davidoff A, Kerns B, et al. Overexpression and mutation of P53 in epithelial ovarian cancer. Cancer Res 1991;52:2979-84.
13. Renninson J, Baker B, McGown A, Murphy D, Norton J, Fox B, Crowther D. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CM1: correlation with histopathology and clinical features. Br J Cancer 1994;69:609-12.
14. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. P53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993;24:1175-9.
15. Niwa K, Itoh M, Murase T, Itoh N, Mori H, Tamaya T. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 1994;70:1191-7.
16. Kiyokawa T. Alteration of p53 in ovarian cancer: its occurrence and maintenance in tumor progression. Int J Gynecol Pathol 1994; 13:311-8.
17. Hartmann L, Podratz K, Keeney G, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994;12:64-9.
18. Sheridan E, Silcocks P, Hancock B, Goyns M. P53 mutation in a series of epithelial ovarian cancers from the U.K. and its prognostic significance. Eur J Cancer 1994;11:1701-4.
19. Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. Mutant p53 portein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-38.
20. Herod J, Eliopoulos A, Warwick J, Niedobitek G, Young L, Kerr D. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56:2178-84.
21. Casey G, Lopez M, Ramos J, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
22. Skilling J, Sood A, Niemann T, Lager D, Buller R. An abundance of p53 null mutations in ovarian carcinoma. Oncogene 1996;13: 117-23.
23. Milner B, Allan L, Eccles D, et al. p53 gene mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993,53:2128-32.
24. Havashi K, Yandell D. How sensitive is PCR-SSCP? Hum Mutat 1993;2:338-46.
25. Kurman R. Blaustein's pathology of the female genital tract, 4th ed. New York, NY: Springer-Verlag, 1994:718-44.
26. Buchman V, Chumakov P, Ninkina N, Samarina O, Georgiev G. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1989;70:245-52.
27. Spinardi L, Mazars R, Theillet C. Protocols for an improved detection of point mutations by SSCP. Nucleic Acids Res 1991;19: 4009.
28. Sanaer F, Nicklen S, Coulson A. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977;74:5463-7.
29. Slatko B. Thermal cycle dideoxy DNA sequencing. Methods Mol Biol 1996;58:413-23.
30. Mok S, Lo K, Taso S. Direct cycle sequencing of mutated alleles detected by PCR single-strand conformation polymorphism analysis. Biotechniques 1993;14:790-4.
31. Runnebaum I, Kohler T, Stickeler E, Kieback H, Kreienberg R. p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma. Br J Cancer 1996;74:1157-60.
32. Friend S. P53: A glimpse at the puppet behind the shadow play. Science 1994;265:334-5.
33. Henriksen R, Oberg K. P53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994;53:301-6.
34. Eccles D, Breet L, Lessells A, Gruber L, Lane D, Steel C, Leonard R. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 1992;40-4.
35. Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S, Hiroshashi S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992;83:978-84.
36. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C. p53 mutations in ovarian cancer a late event? Oncogene 1991;6:1685-90.
37. Kupryjanczyk J, Bell D, Dimeo D, Yandell D, Scully R, Thor A. p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 1994;102:671-6.
38. McManus D, Yap E, Maxwell P, Russell S, Toner P, Mcgee J. p53 expression, mutation, and allelic deletion in ovarian cancer. J Parhol 1994;174:159-68.
39. Wertheim I, Muto M, Welch W, Bell D, Berkowitz R, Mok S. p53 gene mutations in human borderline epithelial ovarian tumors. JNCI 1994;:1549-51.
40. Inoue M, Fujita M, Enomoto T, Morimoto H, Monden T, Shimano T, Tanizawa O. Immunohistochemical analysis of p53 in gynecologic tumors. Am J Clin Pathol 1994;102:665-70.
41. Lee J, Kang Y, Park S, Kim B, Lee E, Lee K, Kavanagh J, Wharton J. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cvtogenet 1995;85:43-50.
42. Klemi P, Takahashi S, Joensuu H, Kiilholma P, Narimatsu E, Mori M. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994; 13:228-33.
43. Klemi P, Pylkkanen L, Kiilholma P, Kuruvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76: 1201-8.
44. Kappes S, Milde-Langosch K, Kressin P, Passlack B, Dockhorn-Dworniczak B, Rohlke P, Loning T. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer 1995;64: 52-9.
45. Reles A, Schmider A, Press M, et al. Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 1996;122: 489-94.
46. Zheng J, Benedict W, Xu H, et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst 1995;87:1146-1153.
47. Teneriello M, Ebina M, Linnoila R, Henry M, Nash J, Park R, Birrer M. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-8.
48. Kupryjanczyk J, Bell D, Dimeo D, Beauchamp R, Thor A, Yandell D. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 1995;26:387-92.
49. Beroud C, Verdier F, Soussi T. p53 gene mutation: software and database. Nucleic Acids Res 1996;24:147-50.
50. Soussi T, May P. Structural aspects of the p53 protein in relation to gene evolution: A second look. J Mol Biol 1996;260:623-37.
51. Arrowsmith C, Morin P. New insights into p53 function from structural studies. Oncogene 1996;12:1379-85.
52. Cho Y, Gorina S, Pavletich N. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
53. Prives C. How loops, beta sheets and alpha helices help us to understand p53. Cell 1994;78:543-6.
54. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1995;1:1029-34.
55. Goh H, Yao J, Smith D. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55:5217-21.
56. Nakai K, Sakamoto H. Construction of a novel database containing aberrant splicing mutations of mammalian genes. Gene 1994;141: 171-7.
57. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris C. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996;24:141-6.
58. Carbone D, Chiba I, Mitsudomi T. Polymorphism at codon 213 within the p53 gene. Oncogene 1991;6:691-2.
59. Felix C, Brown D, Mitsudomi T, et al. Polymorphism at codon 36 of the p53 gene. Oncogene 1994;9:327-8.
60. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
61. Dowell S, Hall P. The clinical relevance of the p53 tumor suppressor gene. Cytopathology 1994;5:133-45.